<p>Clal Insurance Enterprises Holdings Ltd 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Teva Pharmaceutical Industries Ltd.（纽约证券交易所代码：TEVA - 免费报告）的持股比例降低了 14.5%。该机构投资者在季度内出售了 5,491,385 股后，持有 32,362,683 股该公司的股票。Teva Pharmaceutical Industries 大约占 Clal Insurance Enterprises Holdings Ltd. 持有资产的 5.3%，是其第四大持仓。截至最近向 SEC 提交的文件，Clal Insurance Enterprises Holdings Ltd. 持有 Teva Pharmaceutical Industries 约 2.82% 的股份，价值 543,026,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
<p>其他几家对冲基金最近也买卖了 TEVA 的股票。Bourgeon Capital Management LLC 在第二季度将其在 Teva Pharmaceutical Industries 的持仓增加了 100.7%。Bourgeon Capital Management LLC 目前持有 723,974 股该公司的股票，价值 12,134,000 美元，此前在上个季度又购买了 363,252 股。Amundi 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 18.5%。Amundi 目前持有 678,758 股该公司的股票，价值 10,080,000 美元，此前在上个季度又购买了 105,846 股。IFM Investors Pty Ltd 在第二季度将其在 Teva Pharmaceutical Industries 的持股增加了 9.4%。IFM Investors Pty Ltd 目前持有 226,534 股该公司的股票，价值 3,797,000 美元，此前在上个季度又购买了 19,447 股。Jump Financial LLC 在第一季度将其在 Teva Pharmaceutical Industries 的持仓提高了 172.1%。Jump Financial LLC 目前持有 1,325,526 股该公司的股票，价值 20,373,000 美元，此前在上个季度又购买了 838,423 股。最后，Financial Sense Advisors Inc. 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 63.5%。Financial Sense Advisors Inc. 目前持有 405,421 股该公司的股票，价值 6,231,000 美元，此前在该期间又购买了 157,421 股。对冲基金和其他机构投资者持有该公司 54.05% 的股票。</p>
<h2>Teva Pharmaceutical Industries 股价上涨 1.1%</h2>
<p>TEVA 股票周三开盘价为 24.86 美元。该公司的速动比率为 0.77，流动比率为 1.06，债务与股本比率为 2.45。该公司的市值为 285.1 亿美元，市盈率为 -155.38，PEG 比率为 1.11，贝塔值为 0.70。该公司的 50 日简单移动平均线为 20.60 美元，200 日简单移动平均线为 18.37 美元。Teva Pharmaceutical Industries Ltd. 的 52 周最低价为 12.47 美元，52 周最高价为 26.38 美元。</p>
<ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
<p>Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）最近在 11 月 5 日（星期三）发布了其财报。该公司报告本季度每股收益为 0.78 美元，超出分析师一致预期的 0.68 美元，超出幅度为 0.10 美元。该公司本季度的收入为 44.8 亿美元，而分析师预期为 43.6 亿美元。Teva Pharmaceutical Industries 的股本回报率为 46.10%，净利润率为 -0.95%。该公司的季度收入较去年同期增长了 3.4%。去年同期，该公司每股收益为 0.69 美元。Teva Pharmaceutical Industries 已将其 2025 财年的指导目标设定为每股收益 2.550-2.650 美元。根据分析师的平均预期，Teva Pharmaceutical Industries Ltd. 预计本年度每股收益为 2.5 美元。</p>
<h2>内部交易活动</h2>
<p>在相关消息中，董事 Roberto Mignone 于 11 月 6 日（星期四）出售了 200,000 股该股票。股份以平均价格 24.11 美元出售，总交易额为 4,822,000.00 美元。交易完成后，该董事持有 495,000 股该公司的股票，估值约为 11,934,450 美元。这代表其持仓减少了 28.78%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士持有该公司 0.49% 的股票。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
<p>几位分析师对该股票发表了评论。摩根大通将 Teva Pharmaceutical Industries 的目标价从 26.00 美元上调至 28.00 美元，并在 11 月 6 日的研究报告中给予该股票 “增持” 评级。华尔街 Zen 在 10 月 11 日的报告中将 Teva Pharmaceutical Industries 的评级从 “买入” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Teva Pharmaceutical Industries 的 “卖出（d-）” 评级。最后，瑞银集团在 9 月 24 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。两位投资分析师对该股票给予 “强力买入” 评级，六位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Teva Pharmaceutical Industries 目前的共识评级为 “买入”，平均目标价为 25.86 美元。</p>
<p><strong>阅读我们关于 TEVA 的最新报告</strong></p>
<h2>Teva Pharmaceutical Industries 公司简介</h2>
<p>（免费报告）</p>
<p>Teva Pharmaceutical Industries Limited 在北美、欧洲、以色列及国际市场开发、生产、营销和分销仿制药、专科药物和生物制药产品。它提供各种剂型的仿制药，如片剂、胶囊、注射剂、吸入剂、液体、透皮贴剂、软膏和乳膏；无菌产品、激素、高效药物和细胞毒性物质的注射剂和固体剂型；以及与医疗器械和组合产品的仿制药。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过戴瓦制药</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>感恩节餐桌上有什么？每道菜的股票推荐</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>为什么家得宝的困境可能是长期投资者的机会</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>高通的多头们正面临越来越小的错误空间</li>
</ul>
<p><strong>想看看其他对 TEVA 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取戴瓦制药有限公司（NYSE:TEVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在戴瓦制药吗？</h2>
<p>在考虑戴瓦制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而戴瓦制药并不在名单上。</p>
<p>虽然戴瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

梯瓦制药

<p>Clal Insurance 在第二季度将其在梯瓦制药的股份减少了 14.5%，目前持有 3236 万股，价值 5.43 亿美元。梯瓦的股票是 Clal 的第四大持仓。其他投资者也调整了持仓，对冲基金持有梯瓦 54.05% 的股票。梯瓦第三季度的收益超出预期，报告每股收益为 0.78 美元，营收为 44.8 亿美元。分析师提高了目标价，摩根大通将目标价设定为 28.00 美元。内部人士罗伯托·米尼翁出售了 20 万股。梯瓦的股票开盘价为 24.86 美元，市值为 285.1 亿美元</p>

<p>Clal Insurance Enterprises Holdings Ltd lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,362,683 shares of the company's stock after selling 5,491,385 shares during the quarter. Teva Pharmaceutical Industries makes up about 5.3% of Clal Insurance Enterprises Holdings Ltd's holdings, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd owned about 2.82% of Teva Pharmaceutical Industries worth $543,026,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>Clal Insurance Enterprises Holdings Ltd 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Teva Pharmaceutical Industries Ltd.（纽约证券交易所代码：TEVA - 免费报告）的持股比例降低了 14.5%。该机构投资者在季度内出售了 5,491,385 股后，持有 32,362,683 股该公司的股票。Teva Pharmaceutical Industries 大约占 Clal Insurance Enterprises Holdings Ltd. 持有资产的 5.3%，是其第四大持仓。截至最近向 SEC 提交的文件，Clal Insurance Enterprises Holdings Ltd. 持有 Teva Pharmaceutical Industries 约 2.82% 的股份，价值 543,026,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of TEVA. Bourgeon Capital Management LLC increased its position in Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock worth $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi boosted its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock worth $10,080,000 after purchasing an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after buying an additional 19,447 shares in the last quarter. Jump Financial LLC raised its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Financial Sense Advisors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after buying an additional 157,421 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了 TEVA 的股票。Bourgeon Capital Management LLC 在第二季度将其在 Teva Pharmaceutical Industries 的持仓增加了 100.7%。Bourgeon Capital Management LLC 目前持有 723,974 股该公司的股票，价值 12,134,000 美元，此前在上个季度又购买了 363,252 股。Amundi 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 18.5%。Amundi 目前持有 678,758 股该公司的股票，价值 10,080,000 美元，此前在上个季度又购买了 105,846 股。IFM Investors Pty Ltd 在第二季度将其在 Teva Pharmaceutical Industries 的持股增加了 9.4%。IFM Investors Pty Ltd 目前持有 226,534 股该公司的股票，价值 3,797,000 美元，此前在上个季度又购买了 19,447 股。Jump Financial LLC 在第一季度将其在 Teva Pharmaceutical Industries 的持仓提高了 172.1%。Jump Financial LLC 目前持有 1,325,526 股该公司的股票，价值 20,373,000 美元，此前在上个季度又购买了 838,423 股。最后，Financial Sense Advisors Inc. 在第一季度将其在 Teva Pharmaceutical Industries 的股份增加了 63.5%。Financial Sense Advisors Inc. 目前持有 405,421 股该公司的股票，价值 6,231,000 美元，此前在该期间又购买了 157,421 股。对冲基金和其他机构投资者持有该公司 54.05% 的股票。</p>
</div><h2>Teva Pharmaceutical Industries Trading Up 1.1%</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 股价上涨 1.1%</h2>
</div><p>TEVA stock opened at $24.86 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market cap of $28.51 billion, a price-to-earnings ratio of -155.38, a PEG ratio of 1.11 and a beta of 0.70. The business has a fifty day simple moving average of $20.60 and a 200-day simple moving average of $18.37. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $26.38.</p>
<div class="lb-trans"><p>TEVA 股票周三开盘价为 24.86 美元。该公司的速动比率为 0.77，流动比率为 1.06，债务与股本比率为 2.45。该公司的市值为 285.1 亿美元，市盈率为 -155.38，PEG 比率为 1.11，贝塔值为 0.70。该公司的 50 日简单移动平均线为 20.60 美元，200 日简单移动平均线为 18.37 美元。Teva Pharmaceutical Industries Ltd. 的 52 周最低价为 12.47 美元，52 周最高价为 26.38 美元。</p>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
</div><p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.10. The firm had revenue of $4.48 billion for the quarter, compared to analysts' expectations of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.69 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries（纽约证券交易所代码：TEVA - 获取免费报告）最近在 11 月 5 日（星期三）发布了其财报。该公司报告本季度每股收益为 0.78 美元，超出分析师一致预期的 0.68 美元，超出幅度为 0.10 美元。该公司本季度的收入为 44.8 亿美元，而分析师预期为 43.6 亿美元。Teva Pharmaceutical Industries 的股本回报率为 46.10%，净利润率为 -0.95%。该公司的季度收入较去年同期增长了 3.4%。去年同期，该公司每股收益为 0.69 美元。Teva Pharmaceutical Industries 已将其 2025 财年的指导目标设定为每股收益 2.550-2.650 美元。根据分析师的平均预期，Teva Pharmaceutical Industries Ltd. 预计本年度每股收益为 2.5 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares of the company's stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 0.49% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Roberto Mignone 于 11 月 6 日（星期四）出售了 200,000 股该股票。股份以平均价格 24.11 美元出售，总交易额为 4,822,000.00 美元。交易完成后，该董事持有 495,000 股该公司的股票，估值约为 11,934,450 美元。这代表其持仓减少了 28.78%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士持有该公司 0.49% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准备在 2025 年飙升的仿制药股票</li>
</ul>
</div><p>Several analysts have commented on the stock. JPMorgan Chase &amp; Co. lifted their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of &#34;Buy&#34; and an average price target of $25.86.</p>
<div class="lb-trans"><p>几位分析师对该股票发表了评论。摩根大通将 Teva Pharmaceutical Industries 的目标价从 26.00 美元上调至 28.00 美元，并在 11 月 6 日的研究报告中给予该股票 “增持” 评级。华尔街 Zen 在 10 月 11 日的报告中将 Teva Pharmaceutical Industries 的评级从 “买入” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Teva Pharmaceutical Industries 的 “卖出（d-）” 评级。最后，瑞银集团在 9 月 24 日的研究报告中将 Teva Pharmaceutical Industries 的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。两位投资分析师对该股票给予 “强力买入” 评级，六位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Teva Pharmaceutical Industries 目前的共识评级为 “买入”，平均目标价为 25.86 美元。</p>
</div><p><strong>Read Our Latest Report on TEVA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TEVA 的最新报告</strong></p>
</div><h2>Teva Pharmaceutical Industries Company Profile</h2>
<div class="lb-trans"><h2>Teva Pharmaceutical Industries 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p>
<div class="lb-trans"><p>Teva Pharmaceutical Industries Limited 在北美、欧洲、以色列及国际市场开发、生产、营销和分销仿制药、专科药物和生物制药产品。它提供各种剂型的仿制药，如片剂、胶囊、注射剂、吸入剂、液体、透皮贴剂、软膏和乳膏；无菌产品、激素、高效药物和细胞毒性物质的注射剂和固体剂型；以及与医疗器械和组合产品的仿制药。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>What is MarketRank™? How to Use it</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过戴瓦制药</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>感恩节餐桌上有什么？每道菜的股票推荐</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>为什么家得宝的困境可能是长期投资者的机会</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>高通的多头们正面临越来越小的错误空间</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TEVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TEVA 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取戴瓦制药有限公司（NYSE:TEVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在戴瓦制药吗？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑戴瓦制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而戴瓦制药并不在名单上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然戴瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

梯瓦制药有限公司 $TEVA 是 Clal Insurance Enterprises Holdings Ltd 的第四大持仓